Clinical Trial News and Research

RSS

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

TherapeuticsMD, Inc., a women's healthcare company, today announced results for the three-month period and full-year ended December 31, 2013.

4 Mar 2014

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

4 Mar 2014

Yoga offers unique benefits for women with breast cancer undergoing radiation therapy

For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to research from The University of Texas MD Anderson Cancer Center.

4 Mar 2014

Brief physical therapy improves symptoms, QoL in urinary incontinence

A 1-month programme of physical therapy results in significant improvements in quality of life among women with urinary incontinence, a clinical trial has found.

3 Mar 2014

Dendreon plans to make PROVENGE available in Europe

Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.

3 Mar 2014

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.

3 Mar 2014

Genervon's GM604 bio-drug receives FDA orphan drug designation for ALS treatment

Genervon Biopharmaceuticals announced today that the U.S. Food and Drug Administration has granted an "orphan drug" designation to Genervon's GM604 (a.k.a. GM6) bio-drug for the treatment of Amyotrophic Lateral Sclerosis (ALS). The FDA also granted GM604 a "fast-track" designation for ALS in 2013.

3 Mar 2014

Researchers develop new handheld electronic device that help overcome hand shakes caused by tremor

For people whose hands shake uncontrollably due to a medical condition, just eating can be a frustrating and embarrassing ordeal - enough to keep them from sharing a meal with others.

3 Mar 2014

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL).

3 Mar 2014

Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

John F. DiPersio, M.D., Ph.D., will be recognized with the 19th Annual American Association for Cancer Research-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9.

3 Mar 2014

Auxilium Pharmaceuticals’ net revenues increase $125.9M to 56%

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory and clinical development progress and future goals and provided financial guidance for 2014.

28 Feb 2014

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer.

28 Feb 2014

Loyola University Medical Center offers new high-tech catheter device for treating atrial fibrillation

Loyola University Medical Center is the first hospital in Illinois to offer a new high-tech catheter device that can improve outcomes of patients treated for atrial fibrillation, the most common irregular heartbeat.

28 Feb 2014

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration's Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.

28 Feb 2014

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Ophthotech Corporation today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business and product development programs.

27 Feb 2014

Sarepta Therapeutics reports non-GAAP net loss of $29.1 million for Q4 2013

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today reported financial results for the three months and year ended December 31, 2013, and provided an update of recent corporate developments.

27 Feb 2014

Adocia reports positive preliminary results for first clinical trial of BioChaperone Combo

Adocia announces today positive preliminary results for the first clinical trial on an innovative formulation combining insulin analog Glargine (Lantus, Sanofi), the gold standard basal insulin, with a rapid-acting insulin analog, Lispro (Humalog, Eli Lilly) using Adocia's BioChaperone technology.

27 Feb 2014

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint.

27 Feb 2014

Tissue repair drug can improve healing rates in people with diabetic foot ulcer

Patients were twice as likely to have a diabetic foot ulcer heal within eight weeks when they were treated with a tissue repair drug versus a placebo, according to new research accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

27 Feb 2014

Researchers discover new target for human antibodies that holds key to vaccine for dengue

Creating a vaccine that protects people from all four types of dengue virus has frustrated scientists for decades. But researchers at the University of North Carolina have discovered a new target for human antibodies that could hold the key to a vaccine for the world's most widespread mosquito-borne disease.

27 Feb 2014

Clinical Trial News and Research

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Yoga offers unique benefits for women with breast cancer undergoing radiation therapy

Brief physical therapy improves symptoms, QoL in urinary incontinence

Dendreon plans to make PROVENGE available in Europe

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Genervon's GM604 bio-drug receives FDA orphan drug designation for ALS treatment

Researchers develop new handheld electronic device that help overcome hand shakes caused by tremor

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

Auxilium Pharmaceuticals’ net revenues increase $125.9M to 56%

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Loyola University Medical Center offers new high-tech catheter device for treating atrial fibrillation

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Sarepta Therapeutics reports non-GAAP net loss of $29.1 million for Q4 2013

Adocia reports positive preliminary results for first clinical trial of BioChaperone Combo

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Tissue repair drug can improve healing rates in people with diabetic foot ulcer

Researchers discover new target for human antibodies that holds key to vaccine for dengue

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery